https://www.nxtpsychedelics.com/news/articles/psychedelics/fsd-pharma-achieves-milestone-in-completion-of-dosing-of-sentinel-subjects-in-first-in-human-clinical-trial-of-lucid-ms-lucid-21-302-for-multiple-sclerosis/